Catalogo Articoli (Spogli Riviste)
OPAC HELP
Titolo: INTERLEUKIN-6-ASSOCIATED ANEMIA - DETERMINATION OF THE UNDERLYING MECHANISM
Autore: ATKINS MB; KAPPLER K; MIER JW; ISAACS RE; BERKMAN EM;
- Indirizzi:
- TUFTS UNIV NEW ENGLAND MED CTR,DIV HEMATOL ONCOL,750 WASHINGTON ST,BOX 245 BOSTON MA 02111 TUFTS UNIV,SCH MED,DIV HEMATOL ONCOL BOSTON MA 02111 SANDOZ PHARMACEUT CORP,CYTOKINE DEV UNIT E HANOVER NJ 00000
- Titolo Testata:
- Blood
fascicolo: 4,
volume: 86,
anno: 1995,
pagine: 1288 - 1291
- SICI:
- 0006-4971(1995)86:4<1288:IA-DOT>2.0.ZU;2-X
- Fonte:
- ISI
- Lingua:
- ENG
- Soggetto:
- HUMAN RECOMBINANT INTERLEUKIN-6; MICE; LEUKEMIA; PRIMATES; INVITRO; INVIVO;
- Tipo documento:
- Article
- Natura:
- Periodico
- Settore Disciplinare:
- Science Citation Index Expanded
- Citazioni:
- 25
- Recensione:
- Indirizzi per estratti:
-
-
-
- Citazione:
- M.B. Atkins et al., "INTERLEUKIN-6-ASSOCIATED ANEMIA - DETERMINATION OF THE UNDERLYING MECHANISM", Blood, 86(4), 1995, pp. 1288-1291
Abstract
Recombinant human interleukin-6 (rhIL-6) is a pluripotent cytokine with proinflammatory, antitumor, and growth factor effects. Clinical investigations of rhIL-6 either alone as immunotherapy or as a colony-stimulating factor in conjunction with chemotherapy have shown a dose-dependent, rapid onset, and largely reversible decrease in venous hematocrit levels. In an effort to determine the mechanism for the rhIL-6-associated anemia, we measured red blood cell volume serially in patientsreceiving rhIL-6 at either 30 mu g/ kg/day as a 120-hour continuous intravenous infusion (renal cell carcinoma) or 100 mu g/kg/d intravenously over 1 hour for 5 days (melanoma) as part of two separate phase IItrials. Radioisotope dilution assays with Cr-51-labeled autologous red blood cells and hemolysis screens were performed on day 1 before theinitiation of therapy and on day 5 shortly before the end of therapy. In the 6 patients studied, the mean decrease in hemoglobin concentration was 1.9 +/- 0.94 g/dL. The mean decrease in the hematocrit level was 6% +/- 2% and the mean increase in total blood volume was 731 +/- 337 mL. These changes were explained by a mean decrease in red blood mass of 106 +/- 109 mL and a mean increase in plasma volume of 743 +/- 289 mL. The decrease in red blood cell mass was largely explained by phlebotomy during the hospitalization, but was not statistically significant (paired t-test, P = .06). All other changes were statistically significant (P < .05). Simple regression analysis indicated that the decrease in hematocrit level and increase in plasma volume were related (y = -1.78 - .0066X; R = -.74). Measurements of lactate dehydrogenase, bilirubin, haptoglobin, and reticulocyte counts and serial stool hemoccults did not indicate hemolysis or blood loss. We conclude that the anemia caused by IL-6 is caused by an increase in plasma volume. (C) 1995 by The American Society of Hematology.
ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 09:51:05